PRPF38A expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 5.25024468345237E-13 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.93010000204552E-08 |
Normal-vs-Stage2 |
1.360000E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
9.521300E-03 |
Stage1-vs-Stage2 |
5.925000E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
5.406200E-02 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
2.379400E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
5.56887869151979E-12 |
Normal-vs-AfricanAmerican |
2.647000E-01 |
Normal-vs-Asian |
7.767800E-02 |
Caucasian-vs-AfricanAmerican |
2.612000E-02 |
Caucasian-vs-Asian |
7.843200E-01 |
AfricanAmerican-vs-Asian |
2.493200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
3.32289999960267E-07 |
Normal-vs-Female |
2.76980000046834E-07 |
Male-vs-Female |
8.555600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.317250E-03 |
Normal-vs-Extreme_Weight |
1.56488999999427E-05 |
Normal-vs-Obese |
1.558060E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
3.471400E-01 |
Normal_Weight-vs-Obese |
2.750200E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
9.641600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
3.125600E-01 |
Normal-vs-Age(41-60Yrs) |
1.720580E-03 |
Normal-vs-Age(61-80Yrs) |
1.77630132824902E-11 |
Normal-vs-Age(81-100Yrs) |
4.906600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.806600E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.304000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.119000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.665400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.546600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.140400E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
1.756160E-01 |
Normal-vs-Grade 3 |
9.486000E-02 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
8.300800E-01 |
Grade 2-vs-Grade 4 |
1.756160E-01 |
Grade 3-vs-Grade 4 |
9.486000E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
4.55719906256036E-11 |
Normal-vs-N1 |
6.975900E-03 |
N0-vs-N1 |
4.708800E-01 |
|
|